Double‐blinded infliximab dose escalation in patients with rheumatoid arthritis

摘要

ObjectiveTo determine the efficacy, safety and pharmacokinetics of infliximab dose escalation in patients with rheumatoid arthritis (RA) who had an inadequate response to 3 mg/kg infliximab treatment or whose disease flared after initially responding.